Combination of the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib has been shown to lead to a further improved overall survival in metastatic melanoma carrying the BRAF V600E mutation, as compared with dabrafenib monotherapy52. The gene discussed is BRAF; the disease is metastatic melanoma.